Coronarin D, a labdane diterpene, inhibits both constitutive and inducible nuclear factor-κB pathway activation, leading to potentiation of apoptosis, inhibition of invasion, and suppression of osteoclastogenesis

The interleukin-1 (IL-1)-receptor-associated kinase (IRAK-1) is essential for IL-1-stimulated nuclear factor κB (NF-κB) activation. To study the role of IRAK-1 in IL-1β signalling, we have generated a set of IRAK-1 variants that express distinct domains of IRAK-1 either alone or in combination and have examined their effects on an NF-κB-responsive reporter in HeLa cells. Unlike full-length IRAK-1, the deletion mutants were unable to activate NF-κB in the absence of cytokine stimulation. However, an IRAK-1 variant lacking only the N-terminal domain retained the ability of the full-length protein to potentiate both IL-1β and tumour necrosis factor α (TNFα)-induced NF-κB activation. In contrast, expression of the N-terminus or the C-terminus of IRAK-1, or a fusion protein incorporating both domains, inhibited both IL-1β- and TNFα-induced effects. Expression of an IRAK-1 variant lacking only the C-terminal domain preferentially inhibited IL-1β versus TNFα-induced NF-κB activation. These data suggest that the C-terminal domain may link IRAK-1 to downstream signalling components common to both the IL-1 and TNF pathways. Furthermore, we have demonstrated that endogenous IRAK-1 becomes phosphorylated upon IL-1β treatment and can be detected along with NF-κB essential modulator (NEMO) and IκB kinase β (IKKβ) in high-molecular-mass complexes of 600–800kDa. Moreover, IRAK-1 could be detected in NEMO immunoprecipitates from IL-1β-stimulated cells. We conclude that IRAK-1 mediates IL-1β signal transduction through a ligand-dependent association of IRAK-1 with the IKK complex.

Download Full-text

Classical and/or alternative NF-κB pathway activation in multiple myeloma

Blood ◽

10.1182/blood-2009-09-243535 ◽

2010 ◽

Vol 115 (17) ◽

pp. 3541-3552 ◽

Cited By ~ 178

Author(s):

Yulia N. Demchenko ◽

Oleg K. Glebov ◽

Adriana Zingone ◽

Jonathan J. Keats ◽

P. Leif Bergsagel ◽

...

Keyword(s):

Multiple Myeloma ◽

Bone Marrow ◽

Alternative Pathway ◽

Critical Role ◽

Nuclear Factor Κb ◽

Alternative Activation ◽

Classical Pathway ◽

Nuclear Factor ◽

Pathway Activation

Abstract Mutations involving the nuclear factor-κB (NF-κB) pathway are present in at least 17% of multiple myeloma (MM) tumors and 40% of MM cell lines (MMCLs). These mutations, which are apparent progression events, enable MM tumors to become less dependent on bone marrow signals that activate NF-κB. Studies on a panel of 51 MMCLs provide some clarification of the mechanisms through which these mutations act and the significance of classical versus alternative activation of NF-κB. First, only one mutation (NFKB2) selectively activates the alternative pathway, whereas several mutations (CYLD, NFKB1, and TACI) selectively activate the classical pathway. However, most mutations affecting NF-κB–inducing kinase (NIK) levels (NIK, TRAF2, TRAF3, cIAP1&2, and CD40) activate the alternative but often both pathways. Second, we confirm the critical role of TRAF2 in regulating NIK degradation, whereas TRAF3 enhances but is not essential for cIAP1/2-mediated proteasomal degradation of NIK in MM. Third, using transfection to selectively activate the classical or alternative NF-κB pathways, we show virtually identical changes in gene expression in one MMCL, whereas the changes are similar albeit nonidentical in a second MMCL. Our results suggest that MM tumors can achieve increased autonomy from the bone marrow microenvironment by mutations that activate either NF-κB pathway.

Download Full-text